Eupraxia Pharmaceuticals Inc. ('Eupraxia” or the 'Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $4.98, demonstrating a +1.32% change from the preceding day's closing price. The stock's change was more than the S&P 500's daily ...

Special Report: LTR Pharma has co-founded and secured a 33% equity ownership in LevOmega, an Australian company focused on ...

Eupraxia Pharmaceuticals Inc. ('Eupraxia” or the 'Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize ...

Verrica CEO Jayson Rieger said a $10 million payment from its licensing partner will immediately strengthen the firm's ...

Though supported by Big Pharmas like Sanofi and Novo Nordisk parent company Novo Holdings, MapLight has readily burned through heaps of cash. The biotech’s current deficit is $251.6 million as of June ...

A new training space for future biopharmaceutical employees is now operational at the Pitt County Technology Enterprise ...

Two relatively unknown biotechs that are developing promising therapies in this field are Terns Pharmaceuticals ( TERN -7.64%) and Rhythm Pharmaceuticals ( RYTM -2.57%). These biotechs could soar ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), a clinical-stage biotech, is pioneering the use of artificial intelligence and ...

Malvern biotech company Ocugen signed a deal for its experimental gene therapy with Kwangdong Pharmaceutical to bring in over $25 million.

Supporting Lexicon Pharmaceuticals’ decision to advance the non-opioid analgesic pilavapadin into late-stage ...